The 12 peptides removed from FDA restriction in 2026: what each one does

A short reference for the compounds named in the 2026 reclassification announcement.

TL;DR

• The 2026 reclassification announcement proposed returning multiple Category 2 peptides to Category 1.
• Category 1 means eligible for 503A compounding — not FDA-approved.
• Effective dates depend on the formal Federal Register notice; patients should expect a phased rollout.

What it is

In February 2026, the U.S. Department of Health and Human Services announced a proposal to return a group of peptides from FDA Category 2 (in plain English: not currently eligible for 503A compounding) back to Category 1 (eligible for compounding). The named peptides span tissue repair, immune signaling, sleep, and longevity research. Formal authority for the change rests with the FDA, which must issue a Federal Register notice for each compound before pharmacies may prepare it (FDA Bulk Drug Substances Nominations).

How it works

Think of FDA categories as labels on different shelves in a storeroom. Category 1 sits on the “open shelf” — compounding pharmacies can pull from it under standard rules. Category 2 sits behind a locked door — pharmacies cannot prepare those compounds while the door is closed. The 2026 announcement is the regulatory equivalent of unlocking the door for a specific list of compounds. The shelf labels do not say anything about whether the compounded product is FDA-approved (it is not) — only whether a 503A pharmacy may prepare it.

Who asks about it

People come to this question after seeing news headlines about peptide “reclassification” or “legalization” and want a concrete list. The honest answer: the announcement matters, the formal Federal Register notice is what unlocks the door, and the list applies to compounding eligibility — not to FDA approval of the finished compounded product.

What the research says

The peptides typically named in the reclassification conversation include BPC-157 (tissue and gut repair research), TB-500 / thymosin beta-4 (tissue repair), KPV (alpha-MSH fragment with anti-inflammatory research), MOTS-c (mitochondria-derived peptide with metabolic research), DSIP (delta sleep-inducing peptide), epitalon (telomere-related research), Selank (anxiolytic research), and Semax (cognitive-function research). Each compound has its own published research base — some thin, some decades-deep — and reclassification does not change that evidence base.

What to know before considering it

Reclassification changes access. It does not change the underlying research, dose responsibility, or the requirement for a licensed clinician evaluation. Patients reading reclassification news should not assume “available now” or “FDA-approved” — both phrases are inaccurate without a Federal Register-effective date and a 503A-pharmacy sourcing path.

The Halftime POV

The reclassification news is real and meaningful — it widens what compounding pharmacies may prepare. It is not, by itself, an endorsement of any specific peptide for any specific use. The honest read is: more access, same homework on the science.

Related reading:

• Category 1 vs Category 2 peptides: the access framework
• The February 2026 HHS announcement on peptide reclassification
• What the April 2026 FDA peptide reclassification path actually means

FAQ

Q: Which peptides were reclassified in 2026? A: The reclassification announcement named several Category 2 peptides — including BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, Selank, and Semax — proposed for return to Category 1. The exact list and effective dates depend on the formal Federal Register action.

Q: Does reclassification mean these are FDA-approved? A: No. Category 1 status means a peptide is eligible for preparation by 503A compounding pharmacies. It does not mean the compounded product is FDA-approved.

Q: When will the reclassified peptides be available? A: Availability depends on the formal Federal Register effective date and on each compounding pharmacy’s individual sourcing. Patients should expect a phased rollout, not a single launch date.

Disclaimer

As of 2026-04-27, several peptides discussed in this article — including BPC-157, TB-500, KPV, MOTS-c, DSIP, epitalon, Selank, and Semax — are classified by the FDA as Category 2, which means they are not currently available from 503A compounding pharmacies. A February 2026 HHS announcement proposed returning these peptides to Category 1 pending formal FDA Federal Register notice. This article is educational and is not medical advice. Halftime Health only prescribes through licensed clinicians in states where our partner physicians are credentialed.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Bulk Drug Substances Nominations for Use in 503A Compounding — FDA
• Federal Register — Daily Updates

This article discusses compounds that are currently under FDA Category 2 review (see our FDA categorization explainer). These compounds are not currently part of Halftime Health’s published protocol catalog. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.